Article Text

Download PDFPDF
Effects of growth factors and receptor blockade on gastrointestinal cancer
  1. R J Playford,
  2. H Wassan,
  3. S Ghosh
  1. Gastroenterology Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, UK
  1. Correspondence to:
    Professor R J Playford
    Gastroenterology Section, Division of Medicine, Imperial College London, Hammersmith Hospital, Ducane Rd, London W12 0NN, UK; r.playfordimperial.ac.uk

Abstract

The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively early stage in translating their use to standard clinical practice. Similarly, peptide and non-peptide antagonists of growth factor receptors show great potential as novel antichemotherapy agents. However, their actual place in clinical practice has yet to be established.

  • EGF, epidermal growth factor
  • EGFR, epidermal growth factor receptor
  • GLP-2, glucagon-like peptide 2
  • TGF-β, transforming growth factor β
  • GnRH, gonadotrophin releasing hormone
  • TKI, tyrosine kinase inhibitor
  • epidermal growth factor
  • receptor blockade
  • gastrointestinal cancer
  • growth factor receptors

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

Linked Articles